Recruiting nowPhase 1
What this trial is trying to do
MGC028 is an antibody–drug conjugate designed to bind ADAM9, a protein found on the surface of some cancer cells, and deliver a cell-killing drug into them. The trial is testing its safety, tolerability and dose, while also recording whether tumours shrink, stay stable or continue to grow.
Because there is no comparison group, the researchers are first asking whether MGC028 can be given safely at useful doses; any tumour control is an exploratory measure rather than a proven benefit. The main improvement being measured is fewer or more manageable treatment-related side effects while establishing a dose for later studies.
Worth knowing: This is a small, non-randomised phase 1 trial, so it is designed mainly to assess safety and dosing, not to show that MGC028 works or extends survival.
Written from the trial's own registry entry to explain what the researchers are testing and why. Nothing here is a result — this trial has not reported one — and it is not a view on whether the treatment works or on whether it would suit you.
| Registry number | NCT06723236 |
|---|---|
| Recruitment | Recruiting now |
| Phase | Phase 1 |
| Design | not randomised, open label |
| Taking part | 124 people (planned) |
| Who can join | aged 18 Years and over |
| Run by | MacroGenics |
| Started | |
| Main results expected | |
| Record last updated |
What is being tested
- Biological MGC028
What it is measuring
Number and Types of Adverse Events (AEs) in Participants Receiving MGC028
This is the trial's main question — the one it is designed and sized to answer. Anything else it reports is a secondary finding, and secondary findings are far more likely to be chance.
Phase 1. Tests safety and dose in a small group. Some people do benefit, but that is not what the trial is designed to find out.
How the researchers describe it
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9.
The main question the study aims to answer is:
* What types of side effects will participants experience when receiving MGC028?
* Can MGC028 cause cancer to shrink, remain stable, or able to control disease progression of participants with advanced solid tumors?Participants will
* Undergo screening procedures to determine eligibility
* Receive study treatments initially every 3 weeks.
* Have blood samples taken for routine and research tests
* Have other examinations to check heart and lung function, and general health status
* Be asked about any side effects that may be happening or other medications you are taking. The study doctor will provide treatment for side effects, if necessary.
* Have the study doctor assess your tumor status at regular intervals to determine how you are responding to treatment.Written by the trial’s sponsor, quoted from its ClinicalTrials.gov record.
What this trial is looking for
- (K/N)RAS mutated
- dMMR / MSI-H
Read automatically from the criteria below, to make the list searchable. It is a summary of what the text mentions, not a decision about whether you qualify — and where the two disagree, the criteria are right and this is wrong.
Who the trial is looking for
Inclusion Criteria
- Participants in dose escalation or supplemental cohorts must have histologically proven unresectable, locally advanced or metastatic solid tumor limited to one of the following types: NSCLC adenocarcinoma, cholangiocarcinoma, colorectal carcinoma (CRC), or pancreatic carcinoma that is refractory to standard therapy, or for which standard therapy does not exist, has proven to be intolerable, or has been refused by the participant.
- Participants in expansion cohorts must have either
- NSCLC adenocarcinoma with
- progression on or following anti-PD-1/PD-L1 inhibitor, unless contraindicated
- progression on or following therapy for actionable mutations (e.g. EGFR or ALK mutations), if present
- no more than 2 prior lines of cytotoxic chemotherapy for advanced or metastatic disease.
- Pancreatic cancer
- following at least 1 systemic therapy
- no more than 2 prior lines of cytotoxic therapy for advanced or metastatic disease.
- Colorectal adenocarcinoma with
- Progression during or following standard therapy with a fluoropyrimidine-based chemotherapy, oxaliplatin and irinotecan unless contraindicated, refused or unavailable
- Progression after prior targeted treatment for CRC with actionable mutations such as EGFR, KRAS, BRAF and MSI- H/dMMR, if present.
- No more that 2 lines of cytotoxic chemotherapy for advanced or metastatic disease
- No m…
This is an extract. Whether you qualify is decided by the trial team against the full criteria, not by reading this page. Read the full eligibility criteria
Where it is running
Running at 7 sites. Listed in: United States.
Individual hospitals, and whether each is currently open, are listed on the registry record. Sites open and close throughout a trial.
Worth asking your oncology team
Being listed here is not a recommendation, and no one page can tell you whether a trial is right for you. These are the questions it raises.
- Is this trial open at a hospital I could realistically travel to?
- Given my stage, my previous treatment and my tumour's molecular profile, would I be eligible?
- What would I be giving up by joining — is the comparison arm the treatment I would otherwise be having?
- What is already known about the safety of what is being tested?
The source
Registry record NCT06723236, registered by MacroGenics on ClinicalTrials.gov, a public database run by the US National Library of Medicine. The details on this page come from that record and are only ever as current as the sponsor has kept it.
This is a listing of a registered clinical trial, reproduced for information. It is not a recommendation, this site has no connection to the trial or its sponsor, and being listed here says nothing about whether the treatment works. Talk to your own oncology team before pursuing any trial.
This article summarises published research for general information. It is not medical advice, and it is not a substitute for a conversation with your own oncology team, who know your case. Do not start, stop, or change any treatment or supplement on the basis of what you read here.